Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Adding Progressive Care (RXMD) $0.04 to Watch List.
Adding to Biotech Stock Review 2022 Watch List.
Speculative, Yes. But Pay Down of $2 Million Toxic Note and...
Provention Bio (PRVB) Gains 26% Last Week.
We're up 106% From Adding to the 2022 Watch List Last July. And up 26% a Week After Urging Holders to Calm...
Our Best Risk to Reward Idea Ever?
Adding Revive Therapeutics (RVVTF, RVV.CN) to the "2022, Biotech 12 Pack, 12 Biotech Stocks We Expect to...
ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio...
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.
Added to 12 Biotech Stocks we Expect to Double List.
The Original Biotech 6-Pack from 2020, is Growing to...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a...
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE